289 related articles for article (PubMed ID: 22391039)
21. Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer.
Zhang W; Stoehlmacher J; Park DJ; Yang D; Borchard E; Gil J; Tsao-Wei DD; Yun J; Gordon M; Press OA; Rhodes K; Groshen S; Lenz HJ
Clin Colorectal Cancer; 2005 Jul; 5(2):124-31. PubMed ID: 16098254
[TBL] [Abstract][Full Text] [Related]
22. miR-409-3p sensitizes colon cancer cells to oxaliplatin by inhibiting Beclin-1-mediated autophagy.
Tan S; Shi H; Ba M; Lin S; Tang H; Zeng X; Zhang X
Int J Mol Med; 2016 Apr; 37(4):1030-8. PubMed ID: 26935807
[TBL] [Abstract][Full Text] [Related]
23. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models.
Ning Y; Manegold PC; Hong YK; Zhang W; Pohl A; Lurje G; Winder T; Yang D; LaBonte MJ; Wilson PM; Ladner RD; Lenz HJ
Int J Cancer; 2011 May; 128(9):2038-49. PubMed ID: 20648559
[TBL] [Abstract][Full Text] [Related]
24. Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis.
Wilson C; Purcell C; Seaton A; Oladipo O; Maxwell PJ; O'Sullivan JM; Wilson RH; Johnston PG; Waugh DJ
J Pharmacol Exp Ther; 2008 Dec; 327(3):746-59. PubMed ID: 18780829
[TBL] [Abstract][Full Text] [Related]
25. Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist.
Dwyer MP; Yu Y; Chao J; Aki C; Chao J; Biju P; Girijavallabhan V; Rindgen D; Bond R; Mayer-Ezel R; Jakway J; Hipkin RW; Fossetta J; Gonsiorek W; Bian H; Fan X; Terminelli C; Fine J; Lundell D; Merritt JR; Rokosz LL; Kaiser B; Li G; Wang W; Stauffer T; Ozgur L; Baldwin J; Taveras AG
J Med Chem; 2006 Dec; 49(26):7603-6. PubMed ID: 17181143
[TBL] [Abstract][Full Text] [Related]
26. Targeting IL-8 in colorectal cancer.
Ning Y; Lenz HJ
Expert Opin Ther Targets; 2012 May; 16(5):491-7. PubMed ID: 22494524
[TBL] [Abstract][Full Text] [Related]
27. A new herbal formula BP10A exerted an antitumor effect and enhanced anticancer effect of irinotecan and oxaliplatin in the colon cancer PDTX model.
Kim J; Kim HY; Hong S; Shin S; Kim YA; Kim NS; Bang OS
Biomed Pharmacother; 2019 Aug; 116():108987. PubMed ID: 31112870
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
Nukatsuka M; Nakagawa F; Takechi T
Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
[TBL] [Abstract][Full Text] [Related]
29. CXCL8 Associated Dendritic Cell Activation Marker Expression and Recruitment as Indicators of Favorable Outcomes in Colorectal Cancer.
Li E; Yang X; Du Y; Wang G; Chan DW; Wu D; Xu P; Ni P; Xu D; Hu Y
Front Immunol; 2021; 12():667177. PubMed ID: 34025668
[TBL] [Abstract][Full Text] [Related]
30. Enhanced antitumor activity of cerulenin combined with oxaliplatin in human colon cancer cells.
Shiragami R; Murata S; Kosugi C; Tezuka T; Yamazaki M; Hirano A; Yoshimura Y; Suzuki M; Shuto K; Koda K
Int J Oncol; 2013 Aug; 43(2):431-8. PubMed ID: 23754252
[TBL] [Abstract][Full Text] [Related]
31. Honokiol augments the anti-cancer effects of oxaliplatin in colon cancer cells.
Hua H; Chen W; Shen L; Sheng Q; Teng L
Acta Biochim Biophys Sin (Shanghai); 2013 Sep; 45(9):773-9. PubMed ID: 23786838
[TBL] [Abstract][Full Text] [Related]
32. Adeno-associated virus-mediated survivin mutant Thr34Ala cooperates with oxaliplatin to inhibit tumor growth and angiogenesis in colon cancer.
Xue Z; Sun PH; Zhu LM; Jiang SH; Qiao MM; Chi AL; Tu SP
Oncol Rep; 2011 Apr; 25(4):1039-46. PubMed ID: 21279308
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of a nitric oxide-releasing nonsteroidal anti-inflammatory drug and cytotoxic drugs in human colon cancer cell lines in vitro and xenografts.
Leonetti C; Scarsella M; Zupi G; Zoli W; Amadori D; Medri L; Fabbri F; Rosetti M; Ulivi P; Cecconetto L; Bolla M; Tesei A
Mol Cancer Ther; 2006 Apr; 5(4):919-26. PubMed ID: 16648562
[TBL] [Abstract][Full Text] [Related]
34. β-Cryptoxanthin Synergistically Enhances the Antitumoral Activity of Oxaliplatin through ΔNP73 Negative Regulation in Colon Cancer.
San Millán C; Soldevilla B; Martín P; Gil-Calderón B; Compte M; Pérez-Sacristán B; Donoso E; Peña C; Romero J; Granado-Lorencio F; Bonilla F; Domínguez G
Clin Cancer Res; 2015 Oct; 21(19):4398-409. PubMed ID: 26023082
[TBL] [Abstract][Full Text] [Related]
35. Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL.
El Fajoui Z; Toscano F; Jacquemin G; Abello J; Scoazec JY; Micheau O; Saurin JC
Gastroenterology; 2011 Aug; 141(2):663-73. PubMed ID: 21683075
[TBL] [Abstract][Full Text] [Related]
36. Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.
Chian S; Li YY; Wang XJ; Tang XW
Asian Pac J Cancer Prev; 2014; 15(6):2911-6. PubMed ID: 24761924
[TBL] [Abstract][Full Text] [Related]
37. Autophagy inhibition sensitizes colon cancer cells to antiangiogenic and cytotoxic therapy.
Selvakumaran M; Amaravadi RK; Vasilevskaya IA; O'Dwyer PJ
Clin Cancer Res; 2013 Jun; 19(11):2995-3007. PubMed ID: 23461901
[TBL] [Abstract][Full Text] [Related]
38. Synergistic inhibition effect of tumor growth by using celecoxib in combination with oxaliplatin.
Zhao S; Cai J; Bian H; Gui L; Zhao F
Cancer Invest; 2009 Jul; 27(6):636-40. PubMed ID: 19387877
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer.
Zeng ZL; Luo HY; Yang J; Wu WJ; Chen DL; Huang P; Xu RH
Clin Cancer Res; 2014 Feb; 20(4):1042-52. PubMed ID: 24277452
[TBL] [Abstract][Full Text] [Related]
40. Variable NF-κB pathway responses in colon cancer cells treated with chemotherapeutic drugs.
Samuel T; Fadlalla K; Gales DN; Putcha BD; Manne U
BMC Cancer; 2014 Aug; 14():599. PubMed ID: 25134433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
